Getinge completes acquisition of Applikon Biotechnology B.V.

news-releasesApplikon Biotechnology B.V.
January 6th 2020

Delft, The Netherlands: – Getinge has completed the previously announced acquisition of 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V.

On December 20, 2019, Getinge announced an agreement to acquire Applikon Biotechnology B.V., a leading company in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology.

All conditions for the transaction and closing have now been fulfilled. The transaction was completed today with effect as from January 1st, 2020.

Long-term, Applikon Biotechnology B.V. is expected to bring a material contribution to Getinge’s Life Science business area in terms of net sales and EBITA. The acquisition broadens Getinge’s position further within solutions for efficient, safe and contamination-free research and production processes in the biopharma segment.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

About Applikon Biotechnology

Netherlands-based Applikon Biotechnology B.V. (Applikon) is a manufacturer that specializes in upstream bioprocess equipment for the life sciences industries. Its mission is to provide reliable solutions for the bioprocess market to enable improved quality of life.

Applikon’s core business is in the development and supply of advanced bioreactor systems from laboratory scale, to pilot, to production scale, partnering with customers to implement scalable platforms from initial screening through development and full-scale production for a global client base that includes pharma and biotech companies, food industry, CROs, CMOs, governmental and academic organizations.

Applikon designs, develops and assembles bioreactor systems, with all design and manufacturing conducted in-house. The Applikon portfolio covers key product and service areas including bioreactor cultivation systems, BioBundle turnkey systems, the unique BioSep Acoustic Perfusion System cell retention device, process control systems to automate bioprocesses and a range of proprietary AppliSens sensors, and automation (monitoring and data management) solutions.

Apart from its standard cultivation and turnkey systems, Applikon also offers Special Projects: custom solutions aimed at helping clients fulfill strategic needs such as long-term development, capability expansion and upscaling.

Applikon is headquartered at Delft in The Netherlands with subsidiaries in the UK, New Jersey and California, USA and a distributor network covering more than 35 countries.


To read original press release from December 20, 2019, click here.